Charles River Laboratories' Q1 Earnings Beat Consensus, Stock Trades Higher On Signs Of Demand Stabilization
1. CRL reported Q1 2025 earnings beating consensus estimates. 2. Revenue decreased by 2.7% year-over-year despite better performance. 3. Adjusted EPS rose to $2.34, surpassing estimates of $2.08. 4. Company raised 2025 adjusted EPS guidance, reflecting optimism. 5. Cost-saving initiatives partially offset revenue declines in various segments.